抗VEGF治疗眼底新生血管性疾病的临床研究进展  

Clinical research progress of anti-VEGF in the treatment of fundus neovascular diseases

作　　者：谭英 冯卓蕾[1] Tan Ying;Feng Zhuolei(Department of Ophthalmology,the First Affiliated Hospital of Harbin Medical University,Harbin 150007,China)

机构地区：[1]哈尔滨医科大学附属第一医院眼科,150007

出　　处：《临床眼科杂志》2023年第3期274-278,共5页Journal of Clinical Ophthalmology

基　　金：国家自然科学基金(81500731);黑龙江省博士后资助经费(LBH-Z16207)。

摘　　要：抗血管内皮生长因子(VEGF)是治疗新生血管性眼底病变(糖尿病黄斑水肿、视网膜静脉阻塞、以及新生血管性年龄相关性黄斑变性)的主流方案。抗VEGF治疗优点在于:足以帮助患者减少新生血管渗漏以恢复视力,但存在频繁注射和治疗不应答的问题。目前针对这些问题的解决方式有:增强抗VEGF药物耐久性及有效性,提出新的治疗方案、给药方式以及寻找新的抗VEGF治疗靶点等。相关临床研究已经取得一定的进展。这些研究成果将在未来的眼底新生血管性疾病治疗中发挥重要的作用,以帮助减少患者以及卫生保健系统的负担。The most common treatment for neovascular fundus illnesses is anti-vascular endothelial growth factor(anti-VEGF)(diabetic macular edema,retinal vein occlusion,and neovascular age-related macular degeneration).Anti-VEGF therapy has the benefit for assisting patients in reducing neovascularization leaking to regain eyesight,but there are drawbacks such as frequent injections and treatment failure.At the moment,the answers to these issues involve finding novel anti-VEGF therapeutic targets,recommending new treatment plans,and improving the durability and efficacy of anti-VEGF medications.Clinical research associated with this field has also achieved some advancements.To lessen the burden on patients and the healthcare system,these discoveries will be crucial in the future treatment of fundus neovascularization illnesses.

关 键 词：抗VEGF 糖尿病黄斑水肿 视网膜静脉阻塞 新生血管性年龄相关性黄斑变性 

分 类 号：R77[医药卫生—眼科]